Prp19 Is an Independent Prognostic Marker and Promotes Neuroblastoma Metastasis by Regulating the Hippo-YAP Signaling Pathway

Overview

Journal Front Oncol

Specialty Oncology

Date 2020 Nov 23

PMID 33224878

Citations 9

Authors

Yuanxia Cai

Kai Chen

Cheng Cheng

Yonghu Xu

Qianqian Cheng

Guofeng Xu

Yeming Wu

Zhixiang Wu

Affiliations

Soon will be listed here.

Abstract

Pre-mRNA processing factor 19 (Prp19) was previously reported to be involved in tumor progression. However, Prp19 expression and its functions remain elusive in neuroblastoma. Here, we aim to identify the functions and mechanisms of Prp19 in neuroblastoma. Neuroblastic tumor tissue microarrays and two independent validation data sets indicate that Prp19 is associated with high-risk markers and bone marrow metastasis and serves as a prognostic marker for worse clinical outcomes with neuroblastoma. Gain- and loss-of-expression assays reveal that Prp19 promotes invasion, migration, and epithelial-mesenchymal transition (EMT) of neuroblastoma cells . Bioinformatics analysis of RNA-seq data shows that the expressions of YAP and its downstream genes are significantly inhibited after downregulation of Prp19. Prp19 and YAP expression in metastatic lymph nodes is higher than neuroblastoma tissue. Further experiments show that Prp19 regulates YAP expression and consequently affects cell invasion, migration, and EMT in neuroblastoma by pre-mRNA splicing of YAP. In conclusion, our findings provide the first evidence that Prp19 is a potential therapeutic target and prognostic biomarker for patients with neuroblastoma.

Citing Articles

High-Titer Anti-ZSCAN1 Antibodies in a Toddler Clinically Diagnosed with Apparent Rapid-Onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation Syndrome.

Tocan V, Nakamura-Utsunomiya A, Sonoda Y, Matsuoka W, Mizuguchi S, Muto Y Int J Mol Sci. 2024; 25(5).

PMID: 38474067 PMC: 10931978. DOI: 10.3390/ijms25052820.

ADGRL4 Promotes Cell Growth, Aggressiveness, EMT, and Angiogenesis in Neuroblastoma via Activation of ERK/STAT3 Pathway.

Geng G, Zhang L, Yu Y, Guo X, Li Q, Ming M Curr Mol Med. 2024; 25(1):45-55.

PMID: 38178660 DOI: 10.2174/0115665240254765231117122210.

Machine-learning radiomics to predict bone marrow metastasis of neuroblastoma using magnetic resonance imaging.

Lv L, Zhang Z, Zhang D, Chen Q, Liu Y, Qiu Y Cancer Innov. 2023; 2(5):405-415.

PMID: 38090385 PMC: 10686185. DOI: 10.1002/cai2.92.

Comprehensive analysis of PRPF19 immune infiltrates, DNA methylation, senescence-associated secretory phenotype and ceRNA network in bladder cancer.

Wang Y, Wang J, He J, Ji B, Pang Z, Wang J Front Immunol. 2023; 14:1289198.

PMID: 38022515 PMC: 10657824. DOI: 10.3389/fimmu.2023.1289198.

Verteporfin-induced proteotoxicity impairs cell homeostasis and survival in neuroblastoma subtypes independent of YAP/TAZ expression.

Condurat A, Aminzadeh-Gohari S, Malnar M, Schider N, Opitz L, Thomas R Sci Rep. 2023; 13(1):3760.

PMID: 36882436 PMC: 9992669. DOI: 10.1038/s41598-023-29796-2.

References

Nallet-Staub F, Marsaud V, Li L, Gilbert C, Dodier S, Bataille V . Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma. J Invest Dermatol. 2013; 134(1):123-132. PMC: 3938155. DOI: 10.1038/jid.2013.319. View

Pastushenko I, Blanpain C . EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol. 2018; 29(3):212-226. DOI: 10.1016/j.tcb.2018.12.001. View

Yin J, Zhu J, Shen X . New insights into pre-mRNA processing factor 19: A multi-faceted protein in humans. Biol Cell. 2012; 104(12):695-705. DOI: 10.1111/boc.201200011. View

Zheng X, Carstens J, Kim J, Scheible M, Kaye J, Sugimoto H . Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015; 527(7579):525-530. PMC: 4849281. DOI: 10.1038/nature16064. View

Minocha R, Popova V, Kopytova D, Misiak D, Huttelmaier S, Georgieva S . Mud2 functions in transcription by recruiting the Prp19 and TREX complexes to transcribed genes. Nucleic Acids Res. 2018; 46(18):9749-9763. PMC: 6182176. DOI: 10.1093/nar/gky640. View

Krebs A, Mitschke J, Losada M, Schmalhofer O, Boerries M, Busch H . The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol. 2017; 19(5):518-529. DOI: 10.1038/ncb3513. View

Decarolis B, Simon T, Krug B, Leuschner I, Vokuhl C, Kaatsch P . Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed. BMC Cancer. 2016; 16:542. PMC: 4964292. DOI: 10.1186/s12885-016-2513-9. View

Confalonieri S, Quarto M, Goisis G, Nuciforo P, Donzelli M, Jodice G . Alterations of ubiquitin ligases in human cancer and their association with the natural history of the tumor. Oncogene. 2009; 28(33):2959-68. DOI: 10.1038/onc.2009.156. View

Smith M, Altekruse S, Adamson P, Reaman G, Seibel N . Declining childhood and adolescent cancer mortality. Cancer. 2014; 120(16):2497-506. PMC: 4136455. DOI: 10.1002/cncr.28748. View

10.

Tas M, Reedijk A, Karim-Kos H, Kremer L, van de Ven C, Dierselhuis M . Neuroblastoma between 1990 and 2014 in the Netherlands: Increased incidence and improved survival of high-risk neuroblastoma. Eur J Cancer. 2019; 124:47-55. DOI: 10.1016/j.ejca.2019.09.025. View

11.

Tu K, Yang W, Li C, Zheng X, Lu Z, Guo C . Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma. Mol Cancer. 2014; 13:110. PMC: 4035898. DOI: 10.1186/1476-4598-13-110. View

12.

Lai C, Lin C, Liao W, Hour T, Wang H, Chuu C . CD44 Promotes Migration and Invasion of Docetaxel-Resistant Prostate Cancer Cells Likely via Induction of Hippo-Yap Signaling. Cells. 2019; 8(4). PMC: 6523775. DOI: 10.3390/cells8040295. View

13.

Chan S, Kao D, Tsai W, Cheng S . The Prp19p-associated complex in spliceosome activation. Science. 2003; 302(5643):279-82. DOI: 10.1126/science.1086602. View

14.

Rosswog C, Schmidt R, Oberthuer A, Juraeva D, Brors B, Engesser A . Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment. Neoplasia. 2017; 19(12):982-990. PMC: 5678736. DOI: 10.1016/j.neo.2017.09.006. View

15.

Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y . Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol. 2010; 28(21):3506-15. DOI: 10.1200/JCO.2009.27.3367. View

16.

Chen K, Xiao H, Zeng J, Yu G, Zhou H, Huang C . Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer. Clin Cancer Res. 2016; 23(13):3428-3441. PMC: 5440213. DOI: 10.1158/1078-0432.CCR-16-2020. View

17.

Wang Y, Chen K, Cai Y, Cai Y, Yuan X, Wang L . Annexin A2 could enhance multidrug resistance by regulating NF-κB signaling pathway in pediatric neuroblastoma. J Exp Clin Cancer Res. 2017; 36(1):111. PMC: 5559827. DOI: 10.1186/s13046-017-0581-6. View

18.

Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J . Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol. 2009; 10(7):663-71. PMC: 3045079. DOI: 10.1016/S1470-2045(09)70154-8. View

19.

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

20.

Alexander N, Sullivan K, Shaikh F, Irwin M . Characteristics and management of ganglioneuroma and ganglioneuroblastoma-intermixed in children and adolescents. Pediatr Blood Cancer. 2018; 65(5):e26964. DOI: 10.1002/pbc.26964. View